[go: up one dir, main page]

RU2019113989A - Лекарственное средство - Google Patents

Лекарственное средство Download PDF

Info

Publication number
RU2019113989A
RU2019113989A RU2019113989A RU2019113989A RU2019113989A RU 2019113989 A RU2019113989 A RU 2019113989A RU 2019113989 A RU2019113989 A RU 2019113989A RU 2019113989 A RU2019113989 A RU 2019113989A RU 2019113989 A RU2019113989 A RU 2019113989A
Authority
RU
Russia
Prior art keywords
derived peptide
lag
gpc3
hsp70
protein
Prior art date
Application number
RU2019113989A
Other languages
English (en)
Other versions
RU2759728C2 (ru
RU2019113989A3 (ru
Inventor
Томоя МИЯКАВА
Сюн ДОИ
Кодзи ТАМАДА
Original Assignee
Ситлимик Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ситлимик Инк. filed Critical Ситлимик Инк.
Publication of RU2019113989A3 publication Critical patent/RU2019113989A3/ru
Publication of RU2019113989A publication Critical patent/RU2019113989A/ru
Application granted granted Critical
Publication of RU2759728C2 publication Critical patent/RU2759728C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001176—Heat shock proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/844—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (47)

1. Лекарственное средство, включающее:
агонист Toll-подобного рецептора и
белок LAG-3, его вариант или производное.
2. Лекарственное средство по п. 1 для комбинированного введения:
агониста Toll-подобного рецептора и
белка LAG-3, его варианта или производного.
3. Лекарственное средство по п. 1 или 2, где агонист Toll-подобного рецептора является агонистом Toll-подобного рецептора 3 или агонистом Toll-подобного рецептора 9.
4. Лекарственное средство по любому из пп. 1-3, где агонистом Toll-подобного рецептора является Поли-I:С или его соль.
5. Лекарственное средство по п. 4, где Поли-I:С является Поли-ICLC.
6. Лекарственное средство по любому из пп. 1-5, где белок LAG-3, его вариант или производное является слитым белком белка LAG-3 и IgG.
7. Лекарственное средство по любому из пп. 1-6, дополнительно включающее по меньшей мере один полученный из ракового антигена пептид.
8. Лекарственное средство по п. 7, где по меньшей мере один полученный из ракового антигена пептид является HSP70-производным пептидом или GРС3-производным пептидом.
9. Лекарственное средство по п. 7 или 8, включающее:
по меньшей мере один тип полученного из ракового антигена пептида, выбранный из группы, состоящей из НSР70-производного пептида и GРС3-производного пептида,
Поли-ICLC и
белок LAG-3 или слитый белок белка LAG-3 и IgG.
10. Лекарственное средство по п. 9, включающее HSP70-производный пептид, имеющий аминокислотную последовательность, представленную SEQ ID No: 7, или GРС3-производный пептид, имеющий аминокислотную последовательность, представленную SEQ ID No: 16.
11. Лекарственное средство по любому из пп. 7-10, включающее по меньшей мере два типа полученных из раковых антигенов пептидов.
12. Лекарственное средство по п. 11, включающее HSP70-производный пептид и полученный из ракового антигена пептид кроме НSР70-производного пептида.
13. Лекарственное средство по п. 11, включающее GPC3-производный пептид и полученный из ракового антигена пептид кроме GРС3-производного пептида.
14. Лекарственное средство по п. 11, включающее HSP70-производный пептид и GРС3-производный пептид.
15. Лекарственное средство по п. 14, включающее HSP70-производный пептид, имеющий аминокислотную последовательность, представленную SEQ ID No: 7, и GPC3-производный пептид, имеющий аминокислотную последовательность, представленную SEQ ID No: 16.
16. Лекарственное средство по п. 12, включающее:
HSP70-производный пептид, полученный из ракового антигена пептид кроме HSP70-производного пептида,
Поли-ICLC и
белок LAG-3 или слитый белок белка LAG-3 и IgG.
17. Лекарственное средство по п. 13, включающее:
GРС3-производный пептид, полученный из ракового антигена пептид кроме GРС3-производного пептида,
Поли-ICLC и
белок LAG-3 или слитый белок белка LAG-3 и IgG.
18. Лекарственное средство по п. 14, включающее:
HSP70-производный пептид, GРС3-производный пептид,
Поли-ICLC и
белок LAG-3 или слитый белок белка LAG-3 и IgG.
19. Лекарственное средство по п. 18, включающее:
HSP70-производный пептид, имеющий аминокислотную последовательность, представленную SEQ ID No: 7, и
GРС3-производный пептид, имеющий аминокислотную последовательность, представленную SEQ ID No: 16.
20. Лекарственное средство по любому из пп. 1-19 для применения в вакцинотерапии рака.
21. Лекарственное средство по любому из пп. 1-20, где лекарственное средство является противоопухолевым средством.
22. Адъювант, включающий:
агонист Toll-подобного рецептора и
белок LAG-3, его вариант или производное,
для применения в индукции специфичного иммунного ответа против раковой клетки.
23. Комбинация, включающая:
агонист Toll-подобного рецептора и
белок LAG-3, его вариант или производное,
для применения в индукции специфичного иммунного ответа против раковой клетки.
RU2019113989A 2016-10-11 2017-04-14 Лекарственное средство RU2759728C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2016-200227 2016-10-11
JP2016200227 2016-10-11
PCT/JP2017/015227 WO2018070069A1 (ja) 2016-10-11 2017-04-14 医薬

Publications (3)

Publication Number Publication Date
RU2019113989A3 RU2019113989A3 (ru) 2020-11-13
RU2019113989A true RU2019113989A (ru) 2020-11-13
RU2759728C2 RU2759728C2 (ru) 2021-11-17

Family

ID=61905333

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019113989A RU2759728C2 (ru) 2016-10-11 2017-04-14 Лекарственное средство

Country Status (11)

Country Link
US (2) US11291718B2 (ru)
EP (1) EP3527216B1 (ru)
JP (1) JP6998880B2 (ru)
CN (1) CN109982711A (ru)
AU (1) AU2017342189B2 (ru)
BR (1) BR112019006075A2 (ru)
CA (1) CA3039033A1 (ru)
ES (1) ES2972560T3 (ru)
RU (1) RU2759728C2 (ru)
TW (1) TW201813664A (ru)
WO (1) WO2018070069A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10526388B2 (en) * 2015-03-09 2020-01-07 Cytlimic Inc. Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cells
CA2981468A1 (en) 2015-04-07 2016-10-13 Cytlimic Inc. Medicine
EP3527216B1 (en) 2016-10-11 2024-02-14 NEC Corporation A medicine comprising a toll-like receptor agonist, lag-3 protein, a hsp70-derived peptide and a gpc3-derived peptide
JPWO2021106978A1 (ru) * 2019-11-27 2021-06-03
WO2025217058A1 (en) * 2024-04-08 2025-10-16 Bonum Therapeutics, Inc. Lag-3-regulatable il-2 receptor agonists
WO2025250885A1 (en) * 2024-05-31 2025-12-04 Oncotelic, Inc. In situ tumor-infiltrating lymphocyte therapeutics for cancer

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196523A (en) 1985-01-01 1993-03-23 The University Of Southern California Control of gene expression by glucose, calcium and temperature
JPH08151396A (ja) 1994-11-28 1996-06-11 Teijin Ltd Ｈｌａ結合性オリゴペプチド及びそれを含有する免疫調節剤
CO4600681A1 (es) * 1996-02-24 1998-05-08 Boehringer Ingelheim Pharma Composicion farmaceutica para la modulacion inmunitaria
EP0893507A1 (en) 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
CZ303703B6 (cs) 1998-12-23 2013-03-20 Pfizer Inc. Monoklonální protilátka nebo její antigen-vázající fragment, farmaceutická kompozice obsahující tuto protilátku nebo fragment, bunecná linie produkující tuto protilátku nebo fragment, zpusob prípravy této protilátky, izolovaná nukleová kyselina kóduj
EP1212422B1 (en) 1999-08-24 2007-02-21 Medarex, Inc. Human ctla-4 antibodies and their uses
AU2002212236A1 (en) 2000-09-13 2002-03-26 Gabriele Multhoff An hsp70 peptide stimulating natural killer (nk) cell activity and uses thereof
KR20040041575A (ko) 2001-07-31 2004-05-17 칼 페터 쇠더스트룀 면역반응의 모듈화 조성물 및 모듈화 방법
TW200413406A (en) 2002-08-26 2004-08-01 Kirin Brewery Peptides and drugs containing the same
CA2511538C (en) 2002-12-30 2013-11-26 3M Innovative Properties Company Immunostimulatory combinations
FR2863890B1 (fr) 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
AU2006244885B2 (en) 2005-05-09 2011-03-31 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
BRPI0610061A2 (pt) 2005-05-19 2016-11-29 Glaxosmithkline Biolog Sa composição de vacina, uso de subunidade b de toxina instável ao calor de e. coli ou um derivado da mesma, métodos para tratar ou previnir doença, para desenvolver uma resposta imune cd8 específica para antígeno, e, processo para produzir uma vacina
CN104877008B (zh) 2005-08-09 2018-06-05 肿瘤疗法·科学股份有限公司 用于hla-a2阳性人群的来自gpc3的癌症排斥抗原肽以及含有该肽的药物
EP2006377A4 (en) 2006-03-28 2009-12-09 Dainippon Sumitomo Pharma Co NEW TUMORANT PEPTIDES
RU2333767C2 (ru) 2006-03-31 2008-09-20 Автономная некоммерческая организация "Институт молекулярной диагностики" (АНО "ИнМоДи") Вакцинные композиции, способы их применения для профилактики и лечения меланомы и генетические конструкции для получения действующих компонентов композиции
CN101311270A (zh) * 2006-08-18 2008-11-26 上海交通大学医学院 一种可诱生细胞免疫应答的真核表达载体及其疫苗
KR101493773B1 (ko) 2006-10-17 2015-03-03 온코세라피 사이언스 가부시키가이샤 Ｍｐｈｏｓｐｈ1 또는 ｄｅｐｄｃ1 폴리펩티드를 발현하는 암에 대한 펩티드 백신
US20100137221A1 (en) 2007-02-27 2010-06-03 University Utah Research Foundation Peptides that interact with topoisomerase i and methods thereof
CA2691357C (en) 2007-06-18 2014-09-23 N.V. Organon Antibodies to human programmed death receptor pd-1
US8742068B2 (en) 2007-07-06 2014-06-03 Universiteit Utrecht Holding B.V. Treatment and prevention of inflammatory diseases and autoimmune diseases
JP2010538655A (ja) 2007-09-12 2010-12-16 アナフォア インコーポレイテッド 自己免疫疾患についてのｈｓｐ７０に基づく治療
KR100900837B1 (ko) 2007-12-07 2009-06-04 (주)두비엘 리포펩타이드와 폴리(ｉ:ｃ)를 아쥬반트로 포함하는 강력한백신 조성물
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
HUE034832T2 (hu) 2008-12-09 2021-12-28 Hoffmann La Roche Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására
CA2777198C (en) 2009-10-06 2018-07-24 Panacela Labs, Inc. Use of toll-like receptor and agonist for treating cancer
SI3279215T1 (sl) 2009-11-24 2020-07-31 Medimmune Limited Usmerjena vezavna sredstva proti B7-H1
WO2012139094A2 (en) * 2011-04-08 2012-10-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Method of developing a vaccine using peptide-poly ic complexes
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
JP2015506698A (ja) * 2012-02-02 2015-03-05 カリフォルニア ステム セル インコーポレイテッド 多能性胚葉起源抗原を提示する癌ワクチン
BR112014019504A2 (pt) 2012-02-07 2017-06-27 La Jolla Inst Allergy & Immunology alérgenos da erva-dos-prados e métodos e usos para modulação de resposta imune
US20130217122A1 (en) 2012-02-21 2013-08-22 The Trustees Of The University Of Pennsylvania Expansion of Interferon-Gamma-Producing T-Cells Using Glypican-3 Peptide Library
WO2013143026A1 (en) 2012-03-31 2013-10-03 Abmart (Shanghai) Co., Ltd Peptide and antibody libraries and uses thereof
TWI693073B (zh) 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
KR20140100420A (ko) * 2013-02-05 2014-08-14 닛토덴코 가부시키가이샤 경피 또는 점막 투여용 백신 조성물
JP6514647B2 (ja) 2013-03-01 2019-05-15 アステックス ファーマシューティカルズ インコーポレイテッド 薬物組み合わせ
EP3137105A4 (en) * 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
TWI687434B (zh) 2014-10-07 2020-03-11 日商賽多利克公司 使用來自hsp70之胜肽之用於治療或預防癌之醫藥組成物、免疫誘導劑、及抗原呈現細胞之製造方法
US10526388B2 (en) 2015-03-09 2020-01-07 Cytlimic Inc. Peptide derived from GPC3, pharmaceutical composition for treatment or prevention of cancer using the same, immunity inducer, and method for producing antigen-presenting cells
CA2981468A1 (en) 2015-04-07 2016-10-13 Cytlimic Inc. Medicine
KR20230147758A (ko) 2016-07-27 2023-10-23 가부시키가이샤 센탄 멘에키 료호 겐큐죠 암 면역 아쥬반트
EP3527216B1 (en) 2016-10-11 2024-02-14 NEC Corporation A medicine comprising a toll-like receptor agonist, lag-3 protein, a hsp70-derived peptide and a gpc3-derived peptide

Also Published As

Publication number Publication date
TW201813664A (zh) 2018-04-16
RU2759728C2 (ru) 2021-11-17
AU2017342189B2 (en) 2023-09-21
EP3527216A1 (en) 2019-08-21
US20220175915A1 (en) 2022-06-09
CN109982711A (zh) 2019-07-05
US11291718B2 (en) 2022-04-05
CA3039033A1 (en) 2018-04-19
EP3527216B1 (en) 2024-02-14
EP3527216A4 (en) 2020-04-01
US20200038508A1 (en) 2020-02-06
BR112019006075A2 (pt) 2019-06-18
WO2018070069A1 (ja) 2018-04-19
US11759518B2 (en) 2023-09-19
ES2972560T3 (es) 2024-06-13
JPWO2018070069A1 (ja) 2019-09-26
RU2019113989A3 (ru) 2020-11-13
JP6998880B2 (ja) 2022-02-10
AU2017342189A1 (en) 2019-05-02

Similar Documents

Publication Publication Date Title
RU2019113989A (ru) Лекарственное средство
JP2023162283A5 (ru)
ES2619077T3 (es) Composiciones farmacéuticas que comprenden un polipéptido que comprende al menos un motivo CXXC y antígenos heterólogos y usos de las mismas
JP2015533376A5 (ru)
JP2016222689A5 (ja) 合成ペプチド及び乾燥粉末薬剤輸送システム
Liu et al. Enhanced immune response induced by a potential influenza A vaccine based on branched M2e polypeptides linked to tuftsin
RU2016122957A (ru) Способы применения интерлейкина-10 для лечения заболеваний и расстройств
JP2016519933A5 (ru)
FI2970398T3 (fi) Rsv f -prefuusioproteiineja ja niiden käyttö
CY1118373T1 (el) Υψηλης συγκεντρωσης υγρες μορφοποιησεις anti-tnfa αντισωματος
JP2008530245A5 (ru)
JP2011521662A5 (ru)
ES2951684T3 (es) Métodos y composiciones para estimular la respuesta inmune
JP2020506690A5 (ru)
EA202090738A1 (ru) Способ безопасного индуцирования иммунитета против rsv
JP2015529678A5 (ru)
JP2018510132A5 (ru)
JP2014508734A5 (ru)
JP2014502961A5 (ru)
Demircan et al. Biotin functionalized self‐assembled peptide nanofiber as an adjuvant for immunomodulatory response
JP2020534874A5 (ru)
RU2017134693A (ru) Лекарственное средство
JP2015524802A5 (ru)
US20230105457A1 (en) Immunogenic Compounds For Treatment Of Adrenal Cancer
KR101751376B1 (ko) 점막 백신